Advanced Development of a Vaccine for Acute Flaccid Myelitis Associated with Enterovirus D68

支持候选产品的高级开发，以供在故意释放或应对由 NIAID A、B 和 C 类优先病原体或新出现的传染病引起的传染病自然爆发后使用。该合同可能支持各个疫苗成分的配制和制造，以及动物模型中的稳定性测试、非临床免疫原性和功效测试、支持 GLP 毒理学的 IND、提交 IND 以及临床安全性和功效评估。该项目的重点是为儿科人群开发急性弛缓性脊髓炎疫苗。

To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation. This project focuses on the development of an Acute Flaccid Myelitis vaccine for pediatric populations.